Roivant Sciences Ltd. (ROIV)
Roivant is a biopharmaceutical company in London developing medicines for immune, inflammatory and lung diseases. It last closed at $38.71 on Nov 17, up 0.26% on the day. ROIV reports earnings on Fri, Feb 5, 2027. The average 12-month price target from 6 analysts is $51.67 (+33.5% from the last close), with a high of $56.00 and a low of $48.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in ROIV, 100% of them bullish and 0% bearish. In the past 30 days there were 5 dark pool prints totaling $11.4M, the largest $7.2M.
Key Stats
Last 12 monthsNot reported for this period.
From ROIV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 6 analysts who set a price target on ROIV in the past 90 days. The average target is $51.67, with a high of $56.00 and a low of $48.00, compared with the last close of $38.71.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Guggenheim | Target raised | Buy | $46 → $48 |
| Nov 10 | HC Wainwright & Co. | Target raised | Buy | $47 → $48 |
| Oct 28 | Citigroup | Target raised | Buy | $46 → $56 |
| Sep 17 | Stifel | Initiated | Buy | $51 |
| Sep 9 | TD Cowen | Target raised | Buy | $41 → $55 |
Technical Analysis
The stock is 2% above its 20 day and 4% above its 50 day average. It is 16% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 54). The nearest support is the Pivot at $38.28, and the nearest resistance the Pivot R1 at $39.17.
| RSI (14) | 53.54 | Middle of its range | Neutral |
| MACD | 0.94 | Above its signal line | Bullish |
| Stochastic | 50.8 | Middle of its range | Neutral |
| ADX (14) | 18.8 | No clear trend | |
| Williams %R | -52.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 10.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +7.4% | Change over 10 sessions | Bullish |
| ATR (14) | $1.53 | Typical daily range, 3.9% of price |
| RSI (14) | 61.20 | Strong, overbought above 70 | Neutral |
| MACD | 2.14 | Below its signal line | Bearish |
| Stochastic | 64.3 | Middle of its range | Neutral |
| ADX (14) | 38.3 | Trending up | |
| Williams %R | -39.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 92.7 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.2% | Change over 10 sessions | Bearish |
| ATR (14) | $2.95 | Typical daily range, 7.6% of price |
What happened before
See how ROIV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ROIV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in ROIV in the last 90 days.
Dark Pool
30DROIV Institutional Ownership
Full report →- ▲330 buying vs 209 selling
- ▲Held by funds +1.8 pts
- ▲Funds holding +19
- ▼Superinvestors: 2 added, 3 cut
- ▲Put/call 0.03 to 0.00
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 522 | 503 | +3.8% |
| In funds' top 10 | 21 | 15 | +40.0% |
| Held by funds | 79.9% | 78.2% | +1.8 pts |
| New / increased | 99 / 231 | 97 / 204 | +9.6% |
| Reduced / sold out | 133 / 76 | 140 / 40 | +16.1% |
| Put/call ratio | 0.00 | 0.03 | −92.3% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ROIV is in one of them and how their past ROIV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ROIV in an article yet. Here's the latest on the wider market.
ROIV Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Lisa McClainR · MI | Sell | $1K – $15K | Oct 31, 2025 | Nov 21, 2025 | 21 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Oct 30, 2025 | Nov 21, 2025 | 22 d |
| Lisa McClainR · MI | Sell | $1K – $15K | Oct 30, 2025 | Nov 21, 2025 | 22 d |
| Lisa McClainR · MI | Buy | $1K – $15K | Jun 17, 2025 | Aug 13, 2025 | 57 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Roivant Sciences
Roivant is a biopharmaceutical company based in London. It develops medicines for patients with immune and inflammatory conditions, including dermatomyositis, non-infectious uveitis and rheumatoid arthritis, as well as pulmonary hypertension linked to interstitial lung disease. Its product candidates are investigational and still require health authority approval. The company also helps build early-stage drug discovery and health technology companies.
- Headquarters
- London



